CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients

Recruiting now · Phase 1/Phase 2

Conditions studied: Kidney Transplant; Complications, CMV

In brief

The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.

Key facts

Study ID

NCT07096453

Run by

University of Minnesota

People needed

30

Starts

2025-10-02

Expected to finish

2027-08-01

Last updated by the study team

2025-10-31

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult (18-70 year old) kidney transplant recipients
• Patients transitioning from conventional CNI-based immunosuppression to co-stimulatory blockade (belatacept) immunosuppression OR patients who are stable on belatacept immunosuppression at the time of initial CYTOGAM infusion
• CMV Ig Seronegative Recipient who received a CMV Ig seropositive Donor
• EBV IgG Positive

You may not qualify if…

• Pregnant people
• Subjects unwilling to sign consent and complete follow up visits
• Subjects with IgA immunodeficiency
• Subjects who are receiving IgG therapy or who have received IgG therapy within two months of study enrollment
• Patients who do not speak English and would need a translator and translated consent materials in order to obtain informed consent

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.